Latest stories on FBIO
Fortress Biotech: 3 Key Takeaways for Long-Term Investors
The Motley Fool64 · neutralproduct/pr
Fortress Biotech (FBIO) Q3 2026 Earnings Call Transcript
The Motley Fool64 · neutralearnings
Fortress Biotech GAAP EPS of -$0.23 beats by $0.04, revenue of $19.16M misses by $2.41M
Seeking Alpha54 · neutralearnings
Fortress Biotech, Inc. (FBIOP) files 8-K: Items 2.02, 9.01
SEC 8-K50 · neutralgeneral
Fortress Biotech Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
Business Insider58 · neutralearnings
Fortress Biotech, Inc. (FBIO) Q3 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
Fortress Biotech Subsidiary Secures Exclusive License for FB-607 IBS-D Treatment (FBIO)
GuruFocus63 · neutralproduct/pr
Fortress Biotech unit licenses FB-607 from Cedars-Sinai
The Fly58 · neutralproduct/pr
Fortress Biotech Announces an Exclusive License Agreement for FB-607 for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D)
GlobeNewswire63 · neutralproduct/pr
Fortress Biotech Announces an Exclusive License Agreement for FB-607 for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D)
Business Insider63 · neutralproduct/pr
Fortress Biotech, Inc. (FBIOP) files 8-K
SEC 8-K50 · neutralgeneral
Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire56 · neutralgeneral
Fortress Biotech (FBIO) Q2 2026 Earnings Call Transcript
Yahoo Top63 · neutralearnings
Fortress Biotech (FBIO) Q2 2026 Earnings Call Transcript
The Motley Fool63 · neutralearnings
Fortress Biotech, Inc. (FBIOP) files 8-K
SEC 8-K50 · neutralgeneral
Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
GlobeNewswire48 · neutralearnings
Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
StockTitan42 · neutralearnings
Fortress Biotech, Inc. (FBIO) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
Fortress Biotech Q2 Earnings Call Highlights
Yahoo Finance63 · neutralearnings
Fortress Biotech Just Netted $159 Million - Its Preferred Shares Could Be The Real Winner
Seeking Alpha63 · neutralgeneral
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
Business Insider56 · neutralgeneral
Fortress Biotech: Cash Above Market Cap And Royalty Upside Make This A Speculative Buy
Seeking Alpha63 · neutralanalyst
Fortress Biotech, Inc. (FBIOP) files 8-K
SEC 8-K50 · neutralgeneral
Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends?
Seeking Alpha58 · neutralgeneral